Roche Holding (SWX: ROG) can add $5 billion in new oncology drugs revenue between 2018-2021. Roche will soon face biosimilar competition for its older oncology drugs ~ Avastin, Herceptin, and Rituxan. In fact, we calculate $3 billion in expected lost sales from patent losses of these drugs...
Roche Holding (SWX: ROG) can add $5 billion in new oncology drugs revenue between 2018-2021. Roche will soon face biosimilar competition for its older oncology drugs ~ Avastin, Herceptin, and Rituxan. In fact, we calculate $3 billion in expected lost sales from patent losses of these drugs...
Share this Article
Recommended